These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39245464)

  • 1. Luteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer.
    Fischer L; Chung RK; Kim ST; Flyckt R; Weinerman R
    J Obstet Gynaecol Res; 2024 Oct; 50(10):1935-1944. PubMed ID: 39245464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Serum LH Levels During Ovarian Stimulation With GnRH Antagonist Protocol Decrease the Live Birth Rate After Fresh Embryo Transfers but Have No Impact in Freeze-All Cycles.
    Luo Y; Liu S; Su H; Hua L; Ren H; Liu M; Wan Y; Li H; Li Y
    Front Endocrinol (Lausanne); 2021; 12():640047. PubMed ID: 33967956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
    Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
    Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified flexible GnRH antagonist protocol using antagonist early cessation and a gonadotropin step-down approach improves live birth rates in fresh cycles: a randomized controlled trial.
    Xu B; Geerts D; Yuan J; Wang M; Li Z; Lai Q; Zheng Y; Liu S; Yang S; Zhu G; Jin L
    Hum Reprod; 2024 Sep; 39(9):1969-1978. PubMed ID: 38942602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cycle regimens for frozen-thawed embryo transfer.
    Ghobara T; Gelbaya TA; Ayeleke RO
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD003414. PubMed ID: 28675921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
    Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
    Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High FSH dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers.
    Munch EM; Sparks AE; Zimmerman MB; Van Voorhis BJ; Duran EH
    Hum Reprod; 2017 Jul; 32(7):1402-1409. PubMed ID: 28472321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis.
    Bosdou JK; Venetis CA; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Mar; 34(3):491-505. PubMed ID: 30689865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent live-birth rate in antagonist IVF/ICSI protocol after oocyte triggering with GnRH agonist supplemented with 1500 r-hCG the day of oocyte retrieval vs r-hCG : A case-control study.
    Cherrière F; Arvis P; Le Pabic E; Bidet M; Jaffré F; Guivarc'h-Levêque A
    J Gynecol Obstet Hum Reprod; 2020 Jun; 49(6):101702. PubMed ID: 32018042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Trigger for Final Follicular Maturation Improves Cumulative Live-Birth Rate in Ovarian Stimulation for Freeze-All
    Zhu H; Zhao C; Pan Y; Zhou H; Jin X; Xu W; Zhang S
    Front Endocrinol (Lausanne); 2021; 12():708247. PubMed ID: 34349729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration.
    Propst AM; Hill MJ; Bates GW; Palumbo M; Van Horne AK; Retzloff MG
    Fertil Steril; 2011 Oct; 96(4):898-904. PubMed ID: 21839437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?
    Kirshenbaum M; Gil O; Haas J; Nahum R; Zilberberg E; Lebovitz O; Orvieto R
    Reprod Biol Endocrinol; 2021 Dec; 19(1):182. PubMed ID: 34886872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility outcomes in women after controlled ovarian stimulation with gonadotropin releasing hormone agonist long protocol: fresh versus frozen embryo transfer.
    Ding X; Yang J; Li L; Yang N; Lan L; Huang G; Ye H
    BMC Pregnancy Childbirth; 2021 Mar; 21(1):207. PubMed ID: 33711956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.